Quantinno Capital Management LP Grows Stock Holdings in Progyny, Inc. $PGNY

Quantinno Capital Management LP increased its position in Progyny, Inc. (NASDAQ:PGNY) by 382.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 144,251 shares of the company’s stock after buying an additional 114,358 shares during the period. Quantinno Capital Management LP’s holdings in Progyny were worth $2,449,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Easterly Investment Partners LLC boosted its stake in shares of Progyny by 197.4% in the fourth quarter. Easterly Investment Partners LLC now owns 146,013 shares of the company’s stock worth $3,750,000 after acquiring an additional 96,912 shares during the period. First Eagle Investment Management LLC raised its stake in Progyny by 40.2% during the 4th quarter. First Eagle Investment Management LLC now owns 212,612 shares of the company’s stock valued at $5,460,000 after purchasing an additional 60,912 shares during the period. CenterBook Partners LP raised its stake in Progyny by 36.2% during the 4th quarter. CenterBook Partners LP now owns 578,171 shares of the company’s stock valued at $14,847,000 after purchasing an additional 153,778 shares during the period. Simcoe Capital LLC purchased a new position in Progyny in the 4th quarter worth approximately $3,902,000. Finally, Calamos Advisors LLC purchased a new position in Progyny in the 1st quarter worth approximately $679,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Price Performance

NASDAQ PGNY opened at $28.10 on Monday. The stock has a market capitalization of $2.20 billion, a PE ratio of 30.54, a P/E/G ratio of 2.23 and a beta of 1.01. The business has a 50 day simple moving average of $29.08 and a two-hundred day simple moving average of $23.42. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $33.06.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.24. The business had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.46 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.17 EPS. On average, analysts anticipate that Progyny, Inc. will post 1.19 EPS for the current fiscal year.

Progyny announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 10.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Progyny

In related news, Director Cheryl Scott sold 7,439 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the sale, the director owned 19,772 shares of the company’s stock, valued at $521,783.08. This represents a 27.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kevin K. Gordon sold 5,500 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total transaction of $137,445.00. Following the transaction, the director owned 9,318 shares of the company’s stock, valued at $232,856.82. This trade represents a 37.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 36,916 shares of company stock valued at $939,875 in the last 90 days. Company insiders own 9.90% of the company’s stock.

Progyny News Summary

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported second-quarter earnings of $0.55 per share, well above the $0.33 consensus estimate, while revenue of $350.5 million modestly exceeded expectations of $348.6 million. Revenue increased 5.3% year over year, and earnings improved from $0.19 per share in the prior-year quarter. Progyny Announces Second Quarter 2026 Results
• Positive Sentiment: Full-year 2026 adjusted EPS guidance of $2.04 to $2.10 is above the analyst consensus of $1.86, signaling confidence in profitability. Full-year revenue guidance of approximately $1.4 billion is broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Neutral Sentiment: CEO Pete Anevski is scheduled to present at the Canaccord Genuity Annual Growth Conference on August 11. The event could provide additional detail on client demand, growth initiatives and the company’s outlook, but it does not immediately change financial results. Progyny to Present at Canaccord Genuity Conference
• Negative Sentiment: Third-quarter revenue guidance of $335 million to $345 million is below the $350.2 million analyst consensus. Although projected EPS of $0.50 to $0.52 exceeds the $0.47 consensus, investors appear more concerned about slower top-line momentum and the possibility that growth remains muted. Why Progyny Shares Are Sliding Today

Analysts Set New Price Targets

PGNY has been the subject of a number of research analyst reports. BTIG Research increased their price objective on shares of Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a report on Friday, July 24th. Bank of America boosted their target price on shares of Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Citigroup restated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Barclays reaffirmed an “equal weight” rating and set a $34.00 target price (up from $27.00) on shares of Progyny in a research note on Tuesday, July 28th. Finally, KeyCorp lifted their price target on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.20.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.